Comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 vs 3q26 Microduplication Syndrome C4755319
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Fetoplacental Androgens Excess and 3q26 Microduplication Syndrome for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
A condition where the placenta and fetus together produce excess androgens, affecting an XX embryo's development. It is present at birth. Multidisciplinary care helps manage physical and hormonal aspects.
3q26 Microduplication Syndrome C4755319
A genetic condition involving extra genetic material at chromosome 3q26, which can cause developmental delays and other features depending on specific genes involved.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Variable
3q26 Microduplication Syndrome C4755319
0-null
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
severe
3q26 Microduplication Syndrome C4755319
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Chronic
3q26 Microduplication Syndrome C4755319
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
No
3q26 Microduplication Syndrome C4755319
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
reproductive
3q26 Microduplication Syndrome C4755319
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
endocrine
3q26 Microduplication Syndrome C4755319
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-fetoplacental-androgens-excess-C5679876 and 3q26-microduplication-syndrome-C4755319 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 3q26 Microduplication Syndrome C4755319 | Discriminating power |
|---|---|---|---|
| Genital appearance at birth | Atypical genital development may occur from prenatal androgen exposure in an XX fetus. | Genital atypicality is not established as a defining feature from the supplied data. | Moderate |
| Developmental delay | Neurodevelopmental delay is not described as a core feature in the source. | Developmental delay may occur, depending on genes within the duplicated 3q26 region. | Moderate |
| Hormonal pattern | Excess fetoplacental androgens are the stated mechanism; exact laboratory cutoffs are not supplied. | A primary androgen excess pattern is not established by the source description. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 when
XX infant with atypical genitalia and suspected prenatal androgen exposure
The source specifically links fetoplacental androgen excess to XX sex development.
Moderate
Endocrine rather than chromosomal mechanism is the working concern
The supplied category is endocrine and reproductive.
Moderate
Birth presentation centers on sex development
The condition is described as present at birth and affecting embryonic development.
Moderate
Choose 3q26 Microduplication Syndrome C4755319 when
Developmental delay with suspected copy-number change
The source describes extra material at 3q26 and variable developmental features.
Moderate
Congenital genetic syndrome is the leading category
The supplied category is genetic and congenital rather than endocrine.
Moderate
Features vary with the genes involved
The description states phenotype depends on specific duplicated genes.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 3q26 Microduplication Syndrome C4755319 | Interpretation |
|---|---|---|---|
| Karyotype or sex-chromosome assessment | Source specifies an XX embryo; confirmatory testing is clinician-directed. | Sex-chromosome result is not specified and does not establish this diagnosis. | An XX result supports the left context but is not diagnostic alone. |
| Chromosomal microarray | A 3q26 duplication is not part of the stated mechanism. | Extra material at 3q26 is the defining genetic finding described. | Microarray or equivalent testing is more relevant to the right condition. |
| Androgen-related endocrine evaluation | Evaluation may address suspected androgen excess; cutoffs are not provided. | No characteristic androgen result is established in the source. | Abnormal hormone results are findings, not a complete diagnosis. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
- Outcome
- Long-term outcome is not established in the source; it is described as severe and chronic.
- Factors
- Hormonal effects, physical findings, and access to multidisciplinary care may influence course.
3q26 Microduplication Syndrome C4755319
- Outcome
- Outcome is not established and may vary; source severity is moderate and course chronic.
- Factors
- Genes included in the duplication and developmental needs may influence outcome.
Time frame: Both are congenital and described as chronic; exact timelines are not supplied.
Prognosis should not be inferred from severity labels alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Physical and hormonal management needs | Multidisciplinary care is described for physical and hormonal aspects. Such endocrine management is not established from the source. Needs should be individualized; no treatment doses are implied. |
| Developmental support needs | Developmental complications are not established by the supplied description. Developmental delay may require educational and developmental support. Severity and specific deficits depend on genes involved and are not fixed. |
| Associated congenital features | Beyond sex development, additional anomalies are not specified. Other features may occur but are not enumerated in the source. Absence of listed features does not exclude either condition. |
Patient education highlights
- HighDiagnosis is specialist-led
These are distinct congenital conditions. Testing and naming should be confirmed by qualified clinicians.
- HighResults versus diagnosis
An abnormal hormone or genetic result needs interpretation and does not by itself prove the full condition.
- MediumCare planning
The left condition may need endocrine and reproductive follow-up; the right may need developmental follow-up.